Intracerebral hemorrhage (ICH) is usually caused by the rupture of small penetrating arteries secondary to hypertensive changes or other vascular abnormalities \[[@b1-ad-9-6-999]-[@b2-ad-9-6-999]\]. ICH accounts for approximately 10-20% of all stroke cases and is associated with high morbidity and mortality \[[@b3-ad-9-6-999]-[@b4-ad-9-6-999]\]. Common factors influencing ICH include hypertension, cigarette smoking, excessive alcohol consumption, decreased low-density lipoprotein (LDL) cholesterol levels, decreased triglyceride (TG) levels and usage of certain drugs \[[@b5-ad-9-6-999]\]. The spontaneous intracerebral hemorrhage results from small vessel disease (SVD) \[[@b6-ad-9-6-999]\]. There are some MRI markers for SVD, like white matter hyperintensity (WMH), lacunar infarctions (LIs), cerebral microbleeds (CMBs) and perivascular spaces (PVS) \[[@b7-ad-9-6-999]\]. WMH, or leukoaraiosis, represents areas of ischemic white matter damage attributed to degenerative changes to small vessels, including intimal hyperplasia, atherosclerosis, lipohyalinosis and amyloidosis \[[@b8-ad-9-6-999]\]. Therefore, WMH might re?ect the vulnerability of individual brains to pathologic insults \[[@b9-ad-9-6-999]\]. Most researches focus on WMH is associated with ischemic stroke and less on ICH. Our previous research shown that WMH progression within the first two years was an independent predictor of LIs development. One previous publication also indicated greater WMH burden was associated with small vessel stroke compared with other ischemic stroke subtypes \[[@b10-ad-9-6-999]\]. However, there are some disputed results on the relationship between WMH and ICH. It was reported that the presence of WMH is an independent risk factor for warfarin-related ICH and ICH after thrombolytic treatment for acute ischemic stroke \[[@b11-ad-9-6-999]-[@b13-ad-9-6-999]\]. Severe WMH are associated with larger ICH volumes and hematoma growth \[[@b14-ad-9-6-999]\]. Increased WMH is an independent predictor of worse functional outcomes in patients after spontaneous ICH \[[@b15-ad-9-6-999]\]. But Dr. Sykora showed that WMH were not associated with initial hematoma volume, hematoma growth, or intraventricular extension. MH were associated with poor outcome independently \[[@b16-ad-9-6-999]\]. Recently, Dr. Boulouis also indicated that the volume of WMH was not related to either hematoma volume or expansion in ICH \[[@b6-ad-9-6-999]\]. Here, we test our hypothesis that the severity and progression of WMH are related to hematoma volume and absorption in retrospective study.

Figure 1.Diagrammatic sketch of the screening process.

MATERIALS AND METHODS
=====================

Study population
----------------

A total of 2338 patients with ICH were studied retrospectively from June 1, 2012, to June 1, 2017, using data from the Drum Tower Hospital imaging center of Nanjing University Medical School. Patients ≥40 years of age were recruited if they had undergone brain computed tomography (CT) within 12 hours of onset of ICH symptoms and received fluid attenuated inversion recovery (FLAIR) and magnetic resonance imaging (MRI) after ICH, and if their baseline clinical and demographic information, including demographic characteristics, medical history, physical examination results and laboratory examination findings, were available. The exclusion criteria included underlying aneurysm, vascular malformation or tumor, head trauma, venous infarction, moyamoya disease, hemorrhagic transformation of ischemic infarction, and previous surgical evacuation or craniectomy. Consequently, 2111 patients were ruled out: complete clinical data were lacking for 472 patients, brain MRI data were not available for 482 patients, FLAIR imaging data were unavailable for 27 patients,241 patients had underlying aneurysm, 230 had vascular malformation or tumor, 136 had head trauma, 8 had intracranial venous sinus thrombosis, 12 had venous infarction, 22 had moyamoya disease, 18 had hemorrhagic transformation of ischemic infarction, and 451 had undergone surgical evacuation or craniectomy, 12 patients were excluded for other reasons. Ultimately, 227 patients, including 44 patients with only baseline CT, 183 patients with baseline and repeated CT and 37 patients with two MRIs were analyzed in this study ([Fig. 1](#F1-ad-9-6-999){ref-type="fig"}). To determine the relation between ICH volume and WMH progression, we selected a total of 37 patients who had undergone another MRI before ICH (the interval between the two examinations was more than one month). The Ethics Committee of Drum Tower Hospital affiliated to Nanjing University Medical School approved this study. The procedures were conducted according to institutional guidelines.

Figure 2.Quantitative steps of ICH volume. (A) Original CT image. (B) The high-density area. (C) A sketch of the high-density area. D) Calculation of ICH volume.

Risk factors
------------

To assess relevant risk factors at baseline, we examined patient demographic characteristics (age, sex and medical history), history of hypertension, history of diabetes mellitus, presence of coronary heart disease, history of dyslipidemia, and past or present cigarette or alcohol use. Patients underwent a physical examination, systolic and diastolic blood pressure was measured, and laboratory examinations including tests for glucose (random blood glucose RBG, fasting blood glucose FBG, postprandial blood glucose PBG and glycosylated hemoglobin (HbAIc), homocysteine (HCY), total cholesterol (TC), high-density lipoprotein cholesterol (HDL), TG, LDL, apolipoprotein A-I (apoA I), urea nitrogen (BUN), creatinine (Cr), uric acid (UA) and coagulation function were performed.

Radiologic data
---------------

### CT acquisition and analysis

The hematoma volumes of the 227 patients were measured with ITK-SNAP software (University of Pennsylvania, Philadelphia, USA; [www.itksnap.org](http://www.itksnap.org)) at baseline. The baseline scan was limited to 12 hours because most of the hematoma expansion occurred within the following ICH onset after first 24 hours \[[@b16-ad-9-6-999]\]. To determine hematoma absorption, we identified 183 patients who underwent a baseline CT scan within 12 hours and a repeated CT scan within 14 days after ICH onset. We remeasured the repeated ICH volume in 183 patients using ITK-SNAP software. The time window of the repeated CT scan was limited to 14 days after ICH onset because most of the hematoma absorption occurred within 14 days ([Fig. 2](#F2-ad-9-6-999){ref-type="fig"}).

### MRI acquisition and analysis

MRI scanning was performed on a 1.5-T or 3.0-T scanner. The scanning protocol included a whole-brain T1 magnetization-prepared rapid gradient echo sequence, a transversal T2-weighted turbo spin echo sequence, and FLAIR pulse sequences. The timing of the MRI scan was 7.5±1.5 days after ICH onset.

###### 

Baseline characteristics classified according to trichotomized Fazekas Score.

                                       Fazekas Score   *P* Value                                                                                                        
  ------------------------------------ --------------- -------------------------------------------------------- ------------------------------------------------------- --------
  Age, y, mean±SD                      63.32±13.33     64.73±12.29[\*](#nt1a-ad-9-6-999){ref-type="table-fn"}   72.10±10.66[\#](#nt1-ad-9-6-999){ref-type="table-fn"}   0.02
  Men, n (%)                           62              92                                                       18                                                      0.52
  Past medical history, n (%)                                                                                                                                           
    Hypertension                       52              94                                                       16                                                      0.24
    Coronary artery disease            10              22                                                       7                                                       0.09
    Diabetes mellitus                  14              29                                                       4                                                       0.56
    Hyperlipidemia                     1               6                                                        0                                                       0.19
  Smoking, n (%)                       22              20                                                       3                                                       0.17
  Alcohol, n (%)                       16              12                                                       2                                                       0.13
  Medications, n (%)                                                                                                                                                    
   Use of antiplatelet agents          3               19                                                       1                                                       0.11
    Use of anticoagulation             0               4                                                        2                                                       0.25
    Use of statin                      1               7                                                        0                                                       0.10
  NIHSS, mean±SD                       4.84±5.50       4.43±4.27[\*](#nt1a-ad-9-6-999){ref-type="table-fn"}     8.67±7.02[\#](#nt1-ad-9-6-999){ref-type="table-fn"}     \<0.01
  Clinical variables, mean±SD                                                                                                                                           
    SBP, mm Hg                         149.76±25.09    152.65±21.15                                             151.76±16.58                                            0.66
    DBP, mm Hg                         87.32±13.59     87.94±16.34                                              82.90±12.38                                             0.38
    FBG, mM                            6.27±2.54       5.83±1.84                                                7.03±3.43                                               0.06
    RBG, mM                            7.18±2.55       7.10±2.59                                                6.66±1.63                                               0.72
    PBG, mM                            8.84±3.30       8.09±2.97                                                8.43±2.46                                               0.28
    HbAIc, %                           5.99±1.12       5.95±1.03                                                5.79±0.67                                               0.77
    HCY, μM                            14.00±4.17      17.35±9.83                                               14.41±6.10                                              0.09
    TC, mM                             4.38±1.19       4.28±0.97                                                3.69±0.88[\#](#nt1-ad-9-6-999){ref-type="table-fn"}     0.03
    TG, mM                             1.57±1.05       1.36±0.82                                                1.74±1.34                                               0.12
    LDL, mM                            2.39±0.91       2.26±0.69                                                1.90±0.69[\#](#nt1-ad-9-6-999){ref-type="table-fn"}     0.04
    HDL, mM                            1.01±0.32       1.07±0.39                                                0.99±0.45                                               0.46
    ApoA I, g/L                        1.02±0.25       1.12±0.52                                                1.01±0.31                                               0.25
    BUN, mM                            6.14±4.94       6.55±6.78                                                6.38±4.14                                               0.89
    Cr, μM                             66.8±23.53      80.8±76.98                                               65.06±17.35                                             0.20
    UA, μM                             297.56±129.91   281.57±120.35                                            255.81±92.68                                            0.39
    Partial thromboplastin time, sec   32.12±32.05     28.82±5.42                                               27.15±7.79                                              0.42
    International Normalized Ratio     1.26±1.59       1.27±2.24                                                1.09±0.14                                               0.91
    Fibrinogen, g/L                    3.7±2.36        3.3±1.18                                                 4.15±3.72                                               0.16
    D-dimer, mg/L                      2.07±3.48       1.27±1.33                                                1.54±2.55                                               0.11
  Radiologic data                                                                                                                                                       
    ICH volume, mL, mean±SD            13.01±13.34     12.23±13.16                                              21.16±31.21[\#](#nt1-ad-9-6-999){ref-type="table-fn"}   \<0.01
    ICH position, n (%)                                                                                                                                                 0.41
  Lobar ICH                            25              46                                                       11                                                      
  Basal ganglia region ICH             44              67                                                       8                                                       
  Brain stem ICH                       1               1                                                        0                                                       
  Intraventricular ICH                 2               0                                                        1                                                       
    Multiple ICH                       4               6                                                        1                                                       
    Cerebellar ICH                     4               7                                                        0                                                       

1 VS 3 Significant difference (P\<0.05),

2 VS 3 Significant difference (P\<0.05)

### Radiological diagnosis of WMH

WMHs are hyperintense on T2-weighted or FLAIR sequences but can appear as isointense or hypointense (although less hypointense than CSF) on T1-weighted sequences, depending on the sequence parameters and the severity of the pathological changes \[[@b17-ad-9-6-999]\]. White matter lesions, characterized by bilateral and mostly symmetrical hyperintensities on T2-weighted MRI, are common in older individuals.

Fazekas scale score
-------------------

The degree of WMH severity was rated visually on axial FLAIR images using the modified Fazekas scale \[[@b18-ad-9-6-999]-[@b19-ad-9-6-999]\], which is the most widely used and validated system for describing WMH severity. This scale divides WMHs into periventricular and deep sites, and periventricular WMHs were graded according to the following patterns: 0 = absent; 1 = caps or pencil-thin lining; 2 = smooth halo; and 3 = irregular periventricular WMH extending into a deep WMH. Deep WMHs were graded according to the following patterns: 0 = absent; 1 = punctate foci; 2 = some confluences of foci; and 3 = large fused areas. The total score (0 to 6) was calculated by adding the scores for periventricular and deep WMHs. Because some hemorrhages obscured the underlying brain parenchyma, we analyzed WMH in the hemisphere without ICH.

###### 

Univariate Risk Factors for Hemorrhage Volume.

                                      Hemorrhage Volume   *P* Value          
  ----------------------------------- ------------------- ------------------ --------------------------------------------------
  Age, y, mean±SD                     64.97±12.73         64.87±12.73        0.95
  Men, n (%)                          70                  64                 0.47
  Past medical history, n (%)                                                
   Hypertension                       82                  80                 0.85
   Coronary artery disease            12                  19                 0.17
   Diabetes mellitus                  23                  20                 0.63
   Hyperlipidemia                     3                   3                  0.99
  Smoking, n (%)                      21                  17                 0.50
  Alcohol, n (%)                      14                  10                 0.40
  Medications, n (%)                                                         
   Use of antiplatelet agents         11                  8                  0.49
   Use of anticoagulation             1                   3                  0.31
   Use of statin                      4                   3                  0.51
  NIHSS, mean±SD                      3.92±4.00           6.01±5.91          \<0.01[\*](#nt2-ad-9-6-999){ref-type="table-fn"}
  Clinical variables, mean±SD                                                
   SBP, mm Hg                         151.47±24.65        151.65±19.53       0.95
   DBP, mm Hg                         86.68±15.88         87.87±14.62        0.56
   FBG, mM                            5.91±2.15           6.27±2.44          0.24
   RBG, mM                            7.30±2.72           6.86±2.23          0.22
   PBG, mM                            8.54±3.06           8.23±3.06          0.49
   HbAIc, %                           6.03±1.12           5.87±0.93          0.32
   HCY, μM                            15.81±9.38          15.93±6.41         0.93
   TC, mM                             4.21±1.07           4.29±1.04          0.56
   TG, mM                             1.47±0.91           1.46±1.02          0.87
   LDL, mM                            2.25±0.751          2.28±0.81          0.83
   HDL, mM                            1.06±0.31           1.02±0.42          0.39
   ApoA I, g/L                        1.12±0.52           1.02±0.31          0.08
   BUN, mM                            6.03±6.13           6.75±5.79          0.37
   Cr, μM                             72.04±33.02         76.92±78.09        0.54
   UA, μM                             285.7±108.19        283.72±148.16      0.91
   Partial thromboplastin time, sec   28.44±7.04          31.22±26.89        0.30
   International Normalized Ratio     1.40±2.69           1.09±0.34          0.23
   Fibrinogen, g/l                    3.56±2.56           3.49±1.20          0.79
   D-dimer, mg/l                      1.06±1.19           2.12±3.19          \<0.01[\*](#nt2-ad-9-6-999){ref-type="table-fn"}
  Radiologic data                                                            
   WMH volume, mm^3^, mean±SD         13345.29±10768.43   16510.27±9888.57   0.02[\*](#nt2-ad-9-6-999){ref-type="table-fn"}
   ICH position, n (%)                                                       0.01[\*](#nt2-ad-9-6-999){ref-type="table-fn"}
  Lobar ICH                           29                  53                 
  Basal ganglia region ICH            71                  48                 
  Brain stem ICH                      2                   0                  
  Intraventricular ICH                1                   2                  
   Multiple ICH                       5                   6                  
   Cerebellar ICH                     6                   4                  

Significant difference (P\<0.05)

Quantitative analysis of WMH volume
-----------------------------------

WMH volumes were quantified using the software programs MRICRON (University of Nottingham School of Psychology, Nottingham, UK; [www.mricro.com](http://www.mricro.com)) and ITK-SNAP ([Fig. 3](#F3-ad-9-6-999){ref-type="fig"}). All scans were checked by visual inspection. First, the MRICRON software was used to extract the effective WMH area, and then, the ITK-SNAP software was used to calculate the WMH volume. Because WMH quantification was affected by hematoma and perihematomal edema, we adopted certain expedients to reduce errors: we excluded cases with very large lesions, mass effects, or hydrocephalus; the time of MRI scan was 7.5±1.5 days after ICH onset to minimize the influence of edema on quantitative WMH measurements.

Statistical analysis
--------------------

Mean (standard deviation) or median (interquartile range) values were adopted to determine whether continuous variables had a normal distribution. Frequencies were used to describe categorical variables. Patients were dichotomized according to baseline ICH volume as measured on CT. The proportion of ICH volume absorption was calculated by subtracting the baseline ICH volume from the follow-up ICH volume on CT scans and dividing this value by the baseline ICH volume. The proportion of ICH absorption was dichotomized according to the repeated ICH volume as measured on CT. To determine the relation between ICH and WMH progression, we defined non-progression as a white matter volume on the second measurement less than or equal to that of the first measurement, and we defined progression as a white matter volume on the second measurement greater than that of the first measurement. We used Bonferroni correction to evaluate differences between the two groups. We used Fisher's exact test to compare dichotomous variables between groups and used the Wilcoxon rank-sum test for comparisons of continuous and ordinal variables. Variables with a P\<0.1 based on univariate regression analyses were included in the multivariate logistic regression models. Statistical significance was set at P\<0.05.

Figure 3.Quantitative steps of WMH volume. (A) Original FLAIR image. (B) The high signal area. C) A sketch of the effective WMH area. (D) Extraction of the effective WMH area.

RESULTS
=======

Baseline characteristics classified according to trichotomized Fazekas scale scores
-----------------------------------------------------------------------------------

According to the Fazekas scale score, the 227 patients were divided into three groups: Group 1 (score of 0-2), Group 2 (score of 3-4), and Group 3 (score of 5-6). As shown in [Table 1](#T1-ad-9-6-999){ref-type="table"}, Groups 1 and 2werecompared to Group 3. Patients with higher WMH scores were older and had higher NIHSS scores. When Group 1 was compared to Group 3, patients with higher WMH scores had lower TC levels, lower LDL cholesterol levels, and larger ICH volume (P\<0.05). However, when Group 1 was compared to Group 2 or when Group 2 was compared to Group 3, no significant differences were observed.

Univariate and multivariate logistic regression analyses of risk factors related to ICH volume
----------------------------------------------------------------------------------------------

As shown in [Table 2](#T2-ad-9-6-999){ref-type="table"}, the hemorrhage volume was correlated with the NIHSS score, apoA I level, D-dimer level, WMH volume and ICH site (P\<0.05). Lobar ICH had a greater ICH volume, but in cases of smaller ICH volume, the most common ICH site was the basal ganglia region. Only WMH volume, ICH position and NIHSS score were independently associated with ICH volume based on the multivariate regression results, as shown in [Table 3](#T3-ad-9-6-999){ref-type="table"}.

###### 

Multivariate logistic regression analysis of risk factors for ICH volume.

                 Odds Ratio   95% CI      *P* Value
  -------------- ------------ ----------- -------------------------------------------------
  NIHSS          1.08         1.01-1.15   0.03[\*](#nt3-ad-9-6-999){ref-type="table-fn"}
  D-Dimer        1.23         0.99-1.53   0.06
  WMH volume     1.00         1.00-1.00   0.049[\*](#nt3-ad-9-6-999){ref-type="table-fn"}
  ApoA I         0.49         0.20-1.80   0.37
  ICH position   1.44         1.09-1.91   0.01[\*](#nt3-ad-9-6-999){ref-type="table-fn"}

Significant difference (P\<0.05)

###### 

Analysis of relationship of hematoma volume and WMH progression.

                                     WMH progress                    
  ---------------------------------- --------------- --------------- -------------------------------------------------
  Age, y, mean±SD                    59.24±19.43     57.90±15.60     0.82
  Men, n (%)                         12              14              0.97
  Past medical history, n (%)                                        
  Hypertension                       7               12              0.25
  Coronary artery disease            0               1               0.26
  Diabetes mellitus                  3               3               0.83
  Hyperlipidemia                     1               0               0.21
  Smoking, n (%)                     1               4               0.19
  Alcohol, n (%)                     1               5               0.10
  Medications, n (%)                                                 
  Use of antiplatelet agents         0               1               0.26
  Use of anticoagulation             0               0               \-
  Use of statin                      1               0               0.21
  Clinical variables, mean±SD                                        
  SBP, mm Hg                         136.65±21.92    145.20±19.17    0.21
  DBP, mm Hg                         77.35±12.61     83.75±10.56     0.10
  FBG, mM                            5.61±1.75       5.48±1.72       0.82
  RBG, mM                            7.32±4.11       6.99±2.70       0.80
  PBG, mM                            8.43±4.09       7.90±2.03       0.67
  HbAIc, %                           6.07±0.67       6.02±1.29       0.93
  TC, mM                             4.02±1.29       3.79±0.69       0.57
  TG, mM                             1.13±0.44       1.37±0.83       0.38
  LDL, mM                            2.15±0.95       1.98±0.52       0.58
  HDL, mM                            1.00±0.28       0.93±0.27       0.57
  ApoA I, g/L                        1.06±0.25       0.98±0.27       0.41
  BUN, mM                            6.54±3.41       5.56±1.50       0.34
  Cr, μM                             87.17±31.23     69.29±25.03     0.12
  UA, μM                             319.00±112.34   297.71±118.94   0.65
  Partial thromboplastin time, sec   32.21±5.19      32.73±11.95     0.89
  International Normalized Ratio     1.10±0.07       1.14±0.28       0.65
  Fibrinogen, g/L                    2.85±1.10       3.36±1.11       0.26
  D-dimer, mg/L                      1.39±1.21       1.20±1.01       0.70
  Radiologic data                                                    
  ICH volume, ml, mean±SD            7.12±9.19       13.59±10.25     0.049[\*](#nt4-ad-9-6-999){ref-type="table-fn"}

Significant difference (P\<0.05)

Analysis of the relationship between hematoma volume and WMH progression
------------------------------------------------------------------------

As shown in [Table 4](#T4-ad-9-6-999){ref-type="table"}, of all 227 patients, thirty-seven patients who had received two MRIs before ICH onset were analyzed (the interval between the two examinations was more than one month). In this subset of patients, WMH progression was correlated with ICH volume (P\<0.05). However, a trend was observed only for the association between WMH progression and hematoma volume because of the low sample size.

Univariate and multivariate logistic regression analyses of risk factors related to the proportion of hemorrhage absorption
---------------------------------------------------------------------------------------------------------------------------

Hemorrhage absorption was correlated with ICH volume, history of hypertension and postprandial blood glucose (PBG). However, no trend of an association between WMH volume and proportion of hematoma absorption was observed ([Table 5](#T5-ad-9-6-999){ref-type="table"}). After adjusting for other confounding variables that could influence ICH absorption, only high ICH volume was independently associated with a high proportion of ICH absorption based on multivariate regression ([Table 6](#T6-ad-9-6-999){ref-type="table"}).

DISCUSSION
==========

The main findings of this study were as follows: 1) there was an independent association between the severity of WMH and the ICH volume in this cohort of patients, according to quantitative WMH measurements and Fazekas scale scores; 2) WMH progression was correlated with increased ICH volume, suggesting that white matter damage might predict ICH volume.

###### 

Univariate analysis of hematoma absorption proportion.

                                     Hemorrhage Absorption Proportion   *P* Value             
  ---------------------------------- ---------------------------------- --------------------- ------------------------------------------------
  Age, y, mean ±SD                   64.35±12.65                        65.47±12.42           0.56
  Men, n (%)                         48                                 63                    0.11
  Past medical history, n (%)                                                                 
  Hypertension                       48                                 91                    0.03[\*](#nt5-ad-9-6-999){ref-type="table-fn"}
  Coronary artery disease            10                                 12                    0.64
  Diabetes mellitus                  11                                 24                    0.34
  Hyperlipidemia                     0                                  3                     0.28
  Smoking, n (%)                     11                                 21                    0.56
  Alcohol, n (%)                     8                                  10                    0.80
  Medications, n (%)                                                                          
  Use of antiplatelet agents         4                                  12                    0.29
  Use of anticoagulation             1                                  3                     0.49
  Use of statin                      1                                  4                     0.65
  NIHSS, mean±SD                     5.44±6.00                          4.58±4.50             0.28
  Clinical variables, mean±SD                                                                 
  SBP, mm Hg                         149.73±26.85                       153.32±19.69          0.30
  DBP, mm Hg                         87.75±15.76                        87.88±14.99           0.95
  FBG, mM                            5.94±2.26                          5.88±1.89             0.84
  RBG, mM                            6.95±2.45                          7.31±2.65             0.40
  PBG, mM                            7.72±2.54                          8.79±3.34             0.04[\*](#nt5-ad-9-6-999){ref-type="table-fn"}
  HbAIc, %                           5.87±0.92                          6.06±1.15             0.33
  HCY, μM                            14.74±7.54                         17.45±8.94            0.14
  TC, mM                             4.25±1.06                          4.28±0.99             0.82
  TG, mM                             1.38±1.00                          1.39±0.78             0.97
  LDL, mM                            2.24±0.83                          2.31±0.71             0.54
  HDL, mM                            1.04±0.38                          1.07±0.39             0.69
  ApoA I, g/L                        1.04±0.29                          1.11±0.53             0.32
  BUN, mM                            5.74±2.73                          6.40±7.07             0.45
  Cr, μM                             66.81±27.10                        79.78±80.87           0.19
  UA, μM                             276.62±94.89                       272.38±123.87         0.81
  Partial thromboplastin time, sec   29.33±5.57                         27.99±5.49            0.12
  International Normalized Ratio     1.06±0.20                          1.29±2.41             0.42
  Fibrinogen, g/l                    3.49±1.14                          3.57±1.87             0.78
  D-dimer, mg/l                      1.91±2.99                          1.41±2.30             0.26
  Radiologic data                                                                             
  WMH volume, mm3, mean±SD           15344.49±10501.54                  14939.61.82±9674.11   0.79
  Fazakse score, mean±SD             2.06±1.12                          2.09±0.97             0.83
  ICH volume, mL, mean±SD            16045.12±14055.45                  11720.40±12750.35     0.03[\*](#nt5-ad-9-6-999){ref-type="table-fn"}
  ICH position, n (%)                                                                         0.16
  Lobar ICH                          26                                 34                    
  Basal ganglia region ICH           37                                 65                    
  Brain stem ICH                     1                                  1                     
  Intraventricular ICH               \--                                \--                   
  Multiple ICH                       1                                  7                     
  Cerebellar ICH                     6                                  3                     

Significant difference (P\<0.05)

WMH is a neuroimaging finding of white matter changes and is thought to be a result of ischemic injury and demyelination \[[@b20-ad-9-6-999]-[@b21-ad-9-6-999]\]. WMHs are related to ischemic stroke \[[@b21-ad-9-6-999]-[@b22-ad-9-6-999]\], ICH, global functional decline \[[@b23-ad-9-6-999]\], and dementia \[[@b24-ad-9-6-999]\]. WMH has been considered to reflect damage to small vessels in periventricular and subcortical areas, and autopsy studies have shown that the pathogenesis of WMH includes myelin pallor, dilatation of perivascular spaces and tissue myelin rarefaction \[[@b25-ad-9-6-999]-[@b26-ad-9-6-999]\]. WMH is associated with certain vascular risk factors, such as age, hypertension, diabetes mellitus, dyslipidemia, and smoking \[[@b26-ad-9-6-999]-[@b28-ad-9-6-999]\]. As shown in our study, the group with the highest Fazekas scale scores had significantly higher age, NIHSS score, and ICH volume but lower TC and LDL cholesterol levels than the group with the lowest Fazekas scale scores (P\<0.05). The more serious the WMH was, the more significant these differences were. The NIHSS is a 15-item neurological function scale used in patients with acute stroke. A higher NIHSS score reflects a worse patient condition. Higher Fazekas scale scores suggest a greater degree of white matter and brain damage, and the Fazekas scale score has a positive correlation with the NIHSS score.

ICH is the second most common subtype of stroke and is a critical disease that usually leads to severe disability or death. Spontaneous ICH has been attributed to the rupture of arteries previously damaged by chronic hypertension. Pathologic changes in ICH include microaneurysms, fibrinoid degeneration and lipohyalinosis. Compared to ischemic stroke, ICH has higher mortality and more severe disability \[[@b29-ad-9-6-999]\]. Therefore, it is important to study the pathophysiology, risk factors, and prognostic factors of ICH. ICH and WMH share several risk factors in common (hypertension, cerebrovascular disease) and may share a common underlying pathological mechanism involving microangiopathy \[[@b15-ad-9-6-999]\]. As a surrogate for cerebral microangiopathy, WMH has been previously associated with increased risk of spontaneous and medication-induced intraparenchymal hemorrhage putatively via changes in vessel wall integrity, disruption of the brain-blood barrier, and loss of tissue density \[[@b8-ad-9-6-999], [@b30-ad-9-6-999], [@b31-ad-9-6-999]\]. The extent of this pathology may contribute to more severe hematomas, more frequent hemorrhage growth, and intraventricular extension. In this study, we dichotomized patients by hemorrhage volume, and we found a significant association between the severity of WMH and hemorrhage volume, which is consistent with the results of Lou \[[@b14-ad-9-6-999]\]. Moreover, in the subgroup in which the relationship between WMH progression and ICH volume was analyzed, we found a positive relationship between the progression of white matter changes and larger ICH volumes. These common pathophysiologic features between WMH and ICH and the impact of WMHs on brain density provide mechanistic links accounting for our findings, whereby hypertension or cerebral amyloid angiopathy (CAA)may play a role in the progression of WMH in association with ICH.

NIHSS scores indicated the degree of disease severity and were closely related to the ICH volume. Higher NIHSS scores were associated with larger ICH volumes. As shown in this study. The ICH site was also associated with ICH volume based on multivariate analysis. It is commonly noted that cerebral hemorrhage occurs most frequently in the lobar and basal ganglia regions. In this study, lobar hemorrhage was associated with greater ICH volume. The pathophysiologic basis for our findings and its potential relation to WMH that frequently accompanies CAA require further investigation.

Known poor prognostic factors of ICH include large hematoma volume, hematoma expansion and absorption, intraventricular hemorrhage, infra-tentorial location, older age, and anticoagulation treatment \[[@b5-ad-9-6-999]\]. With regard to acute brain bleeding, a large case-control study showed that extensive white matter lesions were associated with lower Glasgow Coma Scale scores and higher mortality \[[@b5-ad-9-6-999]\]. However, our study did not find a clear relationship between the severity of WMH and ICH absorption, as ICH absorption was related to only the initial ICH volume. Further research is needed to explore the relationship between the burden of WMH and ICH absorption.

###### 

Multivariate Logistic Regression Analysis of Risk Factors for Hematoma Absorption Proportion.

                 Odds Ratio   95% CI      *P* Value
  -------------- ------------ ----------- ------------------------------------------------
  Hypertension   0.56         0.24-1.33   0.19
  ICH volume     1.00         1.00-1.00   0.02[\*](#nt6-ad-9-6-999){ref-type="table-fn"}
  PBG            1.12         0.99-1.28   0.08

Significant difference (P\<0.05)

Limitations
-----------

The limitations of our study are as follows. First, this was a single-center, retrospective cohort study design, which should not be extensively relied upon in clinical practice. Future prospective studies should address these limitations. Second, hematoma growth was examined in a small subset of 37 patients. These results, therefore, should be considered preliminary and hypothesis-generating. Further prospective investigations in larger cohorts are needed to confirm the results. Finally, although some measures have been taken to reduce error, the calculated white matter volume was not accurate because the WMH quantification was affected by many factors. Recently, it has been shown that diffusion tensor imaging (DTI) is useful for detecting microstructural abnormalities in white matter. Thus, DTI is expected to supersede conventional methods of WMH measurement in the future \[[@b32-ad-9-6-999]\].

Conclusions
-----------

In conclusion, it was found that the severity and progression of WMH were correlated with ICH volume in patients with ICH. Our findings suggest that WMH may provide important prognostic information about patients with ICH and provide implications for the prevention and treatment of WMH formation or progression. To reduce the occurrence of ICH and improve the functional outcomes of patients after ICH, WMH should be addressed at the early stages of WMH development in clinical practice. Further studies are needed to elucidate the pathophysiologic link between WMH and ICH and to confirm our findings.
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